Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY001 in Healthy Volunteers
Key Insights
Spyre Therapeutics reports positive interim results from its Phase 1 trial of SPY001, a novel half-life extended anti-α4β7 (search) antibody.
The trial, conducted on healthy volunteers, aimed to assess the safety, tolerability, and pharmacokinetics of SPY001.
SPY001 is being developed for the treatment of inflammatory bowel disease (search) (IBD) with the goal of improved efficacy and convenience.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) has announced interim results from its Phase 1 healthy volunteer trial of SPY001, a novel half-life extended anti-α4β7 (search) antibody being developed for the treatment of inflammatory bowel disease (search) (IBD). The company will host a conference call and webcast on November 12, 2024, to discuss the findings. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of SPY001 in healthy participants.
SPY001: A Novel Approach to IBD Treatment
SPY001 represents Spyre's attempt to create a next-generation IBD therapeutic. IBD, encompassing conditions like Crohn's disease and ulcerative colitis, affects millions worldwide, causing chronic inflammation of the gastrointestinal tract. Current treatments often require frequent administration and may not provide adequate relief for all patients. SPY001, with its extended half-life, aims to improve patient convenience and potentially enhance efficacy by maintaining therapeutic drug levels over a longer period.
Conference Call and Webcast Details
Spyre Therapeutics will provide a detailed review of the interim Phase 1 results during a conference call and live webcast scheduled for November 12, 2024, at 8:00 AM ET. Interested parties can access the webcast through the Investor Relations section of Spyre's website.
Spyre Therapeutics' Broader Pipeline
Beyond SPY001, Spyre Therapeutics is focused on developing a pipeline of IBD products using antibody engineering, rational therapeutic combinations, and precision medicine approaches. Their pipeline includes investigational extended half-life antibodies targeting TL1A (search) and IL-23 (search), in addition to α4β7 (search).